RNA Interference Technology Market - Global Forecast 2026-2032 AI-Enabled Discovery And Extrahepatic Delivery Drive 12.96% CAGR And USD 8.26 Billion Opportunity


Date:

(MENAFN- GlobeNewsWire - Nasdaq) Maximize RNAi returns through extrahepatic delivery, AI-enabled discovery, scalable manufacturing, resilient supply chains, and payer-ready evidence.

Dublin, Nov. 19, 2026 (GLOBE NEWSWIRE) -- "RNA Interference Technology Market - Global Forecast 2026-2032" has been added to ResearchAndMarkets.com's offering.

The RNA Interference Technology Market research report provides a comprehensive assessment of the technologies, therapeutic applications, competitive developments, and regional dynamics shaping this rapidly expanding field. The market is projected to reach USD 3.95 billion in 2026 and grow at a CAGR of 12.96% to USD 8.26 billion by 2032.

Market Overview

RNA interference (RNAi) is a validated gene-silencing platform that uses small interfering RNA, microRNA modulation, and related double-stranded RNA approaches to reduce disease-driving messenger RNA before harmful proteins are produced. The field has progressed from discovery biology to approved therapeutics, functional genomics, agricultural biotechnology, and precision medicine.

Commercial momentum is supported by approved siRNA drugs, including patisiran, givosiran, lumasiran, inclisiran, vutrisiran, and nedosiran. These therapies demonstrate RNAi's clinical potential across rare diseases, cardiometabolic disorders, and renal, metabolic, and liver-targeted indications. The market outlook gives decision-makers a practical foundation for evaluating investment priorities, development pipelines, and market-entry opportunities.

Transformative Shifts in the RNAi Landscape

RNAi development is expanding beyond specialized rare-disease programs into chronic and high-burden conditions. Key areas of opportunity include:

  • Cardiometabolic and renal diseases
  • Ophthalmic and neurological disorders
  • Oncology and infectious diseases
  • Genetically defined and previously undruggable targets

Durable gene silencing, infrequent dosing, and target specificity strengthen RNAi's value proposition relative to conventional small molecules and monoclonal antibodies. Delivery remains the most important competitive frontier, led by GalNAc-siRNA conjugates for hepatocyte targeting and lipid nanoparticles for broader tissue access. Extrahepatic ligands, inhaled delivery, intrathecal administration, intravitreal delivery, and other localized approaches are also expanding the addressable market.

Regulatory expectations surrounding off-target effects, immunogenicity, biodistribution, drug interactions, manufacturing controls, and long-term safety make platform quality a critical differentiator.

Artificial Intelligence in RNAi Development

Artificial intelligence is accelerating target prioritization, siRNA sequence design, off-target prediction, toxicity screening, and delivery formulation optimization. Machine learning models using transcriptomic, proteomic, genomic, structural, and clinical data can reduce the number of low-probability candidates entering expensive laboratory validation.

AI also supports biomarker discovery, patient segmentation, trial enrichment, and real-world evidence analysis. Experimental confirmation remains essential, with successful programs requiring reproducible pharmacokinetic, pharmacodynamic, manufacturing, preclinical, and clinical evidence. These insights support risk mitigation by helping organizations distinguish promising platform capabilities from approaches requiring further validation.

Regional and Economic Group Insights

  • North America: Leads through FDA experience, biotechnology clusters, venture financing, academic research, and clinical trial infrastructure.
  • Europe: Benefits from EMA oversight, rare-disease networks, genomic medicine initiatives, cross-border research, and established pharmaceutical ecosystems.
  • Asia-Pacific: Gains momentum through China's pipeline expansion, India's contract research and manufacturing capacity, Japan's regulatory maturity, South Korea's biotech investment, and Australia's early-phase trial capabilities.
  • Latin America: Brazil and Mexico provide important clinical access, research participation, and commercialization opportunities.
  • Middle East and Africa: GCC genomics programs are supporting precision medicine adoption, while Africa presents longer-term potential in infectious disease, agriculture, and public health applications.

G7 markets remain central to commercialization due to mature regulation, reimbursement systems, intellectual property protection, and advanced manufacturing standards. BRICS, ASEAN, and GCC markets offer strategic growth potential through large patient populations, expanding research activity, manufacturing investment, and national precision medicine programs. Country-level comparisons enable more informed regional partnerships and market-access planning.

Strategic Priorities for Industry Leaders

  • Advance safe, scalable delivery beyond the liver.
  • Invest in GalNAc, lipid nanoparticles, local delivery, ligand discovery, and endosomal escape technologies.
  • Combine AI-enabled discovery with rigorous laboratory validation.
  • Select indications using clear clinical, regulatory, and commercial criteria.
  • Build payer-ready evidence demonstrating durable outcomes and reduced dosing burden.
  • Strengthen regional clinical partnerships, quality systems, and supply-chain resilience.

Key Takeaways from This Report

  • The market is forecast to grow from USD 3.95 billion in 2026 to USD 8.26 billion by 2032.
  • Delivery innovation is the primary driver of clinical and commercial differentiation.
  • AI is improving RNAi discovery efficiency but does not replace experimental validation.
  • Expansion into chronic diseases and extrahepatic targets creates significant new opportunities.
  • Regulatory rigor, scalable manufacturing, reimbursement evidence, and regional access strategies will determine long-term competitiveness.

Key Attributes:

Report Attribute Details
No. of Pages 191
Forecast Period 2026 - 2032
Estimated Market Value (USD) in 2026 $3.95 Billion
Forecasted Market Value (USD) by 2032 $8.26 Billion
Compound Annual Growth Rate 12.9%
Regions Covered Global


Key Topics Covered:
1. Preface
1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders
2. Research Methodology
2.1. Introduction
2.2. Research Design
2.2.1. Primary Research
2.2.2. Secondary Research
2.3. Research Framework
2.3.1. Qualitative Analysis
2.3.2. Quantitative Analysis
2.4. Market Size Estimation
2.4.1. Top-Down Approach
2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations
3. Executive Summary
3.1. Introduction
3.2. CXO Perspective
3.3. New Revenue Opportunities
3.4. Next-Generation Business Models
3.5. Industry Roadmap
4. Market Overview
4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
4.2.1. Supply-Side Analysis
4.2.2. Demand-Side Analysis
4.2.3. Stakeholder Analysis
4.3. Market Dynamics
4.3.1. Key Drivers
4.3.2. Key Restraints
4.3.3. Key Opportunities
4.3.4. Key Challenges
4.4. Porter's Five Forces Analysis
4.5. PESTLE Analysis
4.6. Market Outlook
4.6.1. Near-Term Market Outlook (0-2 Years)
4.6.2. Medium-Term Market Outlook (3-5 Years)
4.6.3. Long-Term Market Outlook (5-10 Years)
4.7. Go-to-Market Strategy
5. Market Insights
5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis
6. Cumulative Impact of Artificial Intelligence 2026

7. RNA Interference Technology Market, by Molecule Type
7.1. Introduction
7.2. MicroRNA (miRNA)
7.3. Short Hairpin RNA (shRNA)
7.3.1. Non-Viral Delivery shRNA
7.3.2. Viral Delivery shRNA
7.4. Small Interfering RNA (siRNA)
7.4.1. Conjugated siRNA
7.4.2. Non-Conjugated siRNA
8. RNA Interference Technology Market, by Route Of Administration
8.1. Introduction
8.2. Intramuscular (IM) Injection
8.3. Intrathecal (IT) Administration
8.4. Intravenous (IV) Injection
9. RNA Interference Technology Market, by Delivery Method
9.1. Introduction
9.2. Direct Naked RNAi Delivery
9.3. Exosome-Based RNAi Therapy
9.4. Nanoparticle-Based Delivery
9.5. Viral Vector-Based Delivery
10. RNA Interference Technology Market, by Application
10.1. Introduction
10.2. Drug Discovery
10.2.1. Lead Optimization
10.2.2. Target Identification
10.3. Research & Development
10.3.1. Gene Function Studies
10.3.2. Pathway Analysis
10.4. Therapeutics
11. RNA Interference Technology Market, by End-User
11.1. Introduction
11.2. Contract Research Organizations
11.3. Hospitals & Clinics
11.4. Pharmaceutical & Biotechnology Companies
12. RNA Interference Technology Market, by Region
12.1. Introduction
12.2. Asia-Pacific
12.3. Europe
12.4. North America
12.5. Latin America
12.6. Africa
12.7. Middle East
13. RNA Interference Technology Market, by Group
13.1. Introduction
13.2. NATO
13.3. G7
13.4. European Union
13.5. BRICS
13.6. ASEAN
13.7. GCC
14. RNA Interference Technology Market, by Country
14.1. Introduction
14.2. United States
14.3. China
14.4. Germany
14.5. Japan
14.6. India
14.7. United Kingdom
14.8. France
14.9. Canada
14.10. Italy
14.11. Australia
14.12. South Korea
14.13. Brazil
14.14. Mexico
14.15. Russia
14.16. Spain
15. Competitive Landscape
15.1. Market Share Analysis, 2025
15.2. Market Concentration Analysis, 2025
15.2.1. Concentration Ratio (CR)
15.2.2. Herfindahl Hirschman Index (HHI)
15.3. Recent Developments & Impact Analysis, 2025
15.4. Product Portfolio Analysis, 2025
15.5. Benchmarking Analysis, 2025
16. Company Profiles
16.1. ADARx Pharmaceuticals Inc
16.2. Alnylam Pharmaceuticals Inc
16.3. Arbutus Biopharma Corporation
16.4. Arcturus Therapeutics Holdings Inc
16.5. Arrowhead Pharmaceuticals Inc
16.6. AstraZeneca PLC
16.7. Avidity Biosciences Inc
16.8. Benitec Biopharma Inc
16.9. BioNTech SE
16.10. City Therapeutics Inc
16.11. Genevant Sciences Ltd
16.12. Intellia Therapeutics Inc
16.13. Ionis Pharmaceuticals Inc
16.14. Moderna Inc
16.15. Novartis AG
16.16. Novo Nordisk A/S
16.17. OliX Pharmaceuticals Inc
16.18. Phio Pharmaceuticals Corp
16.19. ProQR Therapeutics NV
16.20. Roche Holding AG
16.21. Sanofi SA
16.22. Sarepta Therapeutics Inc
16.23. Silence Therapeutics PLC
16.24. Sirnaomics Inc
16.25. Suzhou Ribo Life Science Co., Ltd
16.26. Vir Biotechnology Inc
16.27. Wave Life Sciences Ltd
17. Key Experts

List of Figures [21]
List of Tables [323]
For more information about this report visit

About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

CONTACT: CONTACT: ResearchAndMarkets.com Laura Wood,Senior Press Manager... For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900

MENAFN19112026004107003653ID1111990506


GlobeNewsWire - Nasdaq

Legal Disclaimer:
MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.



More Story

Search